echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > First discovery: a cytokine storm appeared after a cancer patient was vaccinated with the new crown mRNA vaccine

    First discovery: a cytokine storm appeared after a cancer patient was vaccinated with the new crown mRNA vaccine

    • Last Update: 2021-06-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Written | Edited by Wang Cong | Nagashi Typesetting | Cytokine Release Syndrome (CRS), also known as Cytokine Storm (Cytokine Storm), is usually caused by microbial infections that cause the body to release a large amount of cytokines A systemic inflammatory response is an important cause of acute respiratory distress syndrome and multiple organ failure.

    In addition to microbial infections such as bacteria and viruses, CAR-T cell therapy is also prone to cytokine storms.
    In addition, cytokine storms may also occur during immune checkpoint inhibitor therapy, but the probability is extremely low.

    In the new crown pneumonia vaccination plan, cancer patients are the priority targets for vaccination, and there is no cytokine storm caused by vaccination.

    On May 26, 2021, researchers from the Francis Crick Institute in the United Kingdom published a research paper titled: Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2 in the top international medical journal Nature Medicine.

    The study found that a patient with colorectal cancer who had received PD-1 therapy for a long time experienced a cytokine storm after being vaccinated with the mRNA new crown vaccine developed by Pfizer/BioNTech.

    This 58-year-old male patient started monotherapy with anti-PD-1 monoclonal antibody in February 2019 for the treatment of his metastatic mismatch repair defective colorectal cancer.

    Two months after the start of treatment, he experienced neuroimmune-related adverse reactions (irAE) under the background of preexisting spinocerebellar ataxia.
    The ataxia worsened, but the cause is unknown, so the anti-PD-1 monoclonal antibody treatment was suspended.
    Then I started taking prednisolone and my ataxia recovered.In June 2019, the patient restarted anti-PD-1 monoclonal antibody treatment and his condition was stable.

    In March 2020, the patient developed an immune-related adverse reaction (irAE) and took prednisolone again, and disease control was maintained.

    On December 2, 2020, the patient received anti-PD-1 monoclonal antibody treatment for the last time.
    On December 29, 27 days later, the patient was vaccinated with the mRNA new crown vaccine BNT162b2 developed by Pfizer/BioNTech.

    The patient had not been infected with the new coronavirus before, and there was no immediate adverse reaction after vaccination.

    On January 3, 2021, 5 days after vaccination (that is, 32 days after the last anti-PD-1 monoclonal antibody treatment), despite taking the thermal analgesic ibuprofen, the patient still developed muscle pain, diarrhea and Fever symptoms.

    Broad-spectrum antibiotic treatment and related tests, and the SARS-CoV-2 RT-PCR test showed that the patient was not infected with the virus, nor was he infected with the new coronavirus.

    For the next 5 days, the patient continued to have a fever of up to 39.
    8 °C, thrombocytopenia, increased inflammation markers, and a significant increase in ferritin.

    After admission, the patient was suspected of having a grade 3 cytokine storm and received intravenous methylprednisolone (IVMP) hormone therapy.

    All indicators began to return to normal after 7 days.

    After being discharged from the hospital and returning home, the patient did not have fever and other symptoms and remained in good condition.

    On February 8, 2021 (36 days after the initial visit), the patient received the anti-PD-1 monoclonal antibody again without any adverse events.

    He did not receive a second dose of mRNA vaccine.

    In the context of anti-PD-1 monotherapy, less than 0.
    01% of immune-related adverse reactions (irAE) involve cytokine storms, and so far, two large-scale vaccinated mRNA vaccines (BNT162b2, mRNA-1273) have not The report causes a cytokine factor storm. The cytokine storm associated with immune checkpoint blocking therapy usually occurs in the 4th week after treatment, and the patient has started the immune checkpoint blocking therapy with anti-PD-1 monoclonal antibody 22 months ago, which makes the treatment not It may be the only reason for the cytokine storm.

    In this case, the close temporal correlation between mRNA vaccination and its clinical manifestations of cytokine storm suggests that mRNA vaccine may be a potential trigger of cytokine storm.

    The author of the paper stated that cancer patients were excluded from the research during the development of the new crown vaccine, but cancer patients were included during the vaccination.
    Therefore, the safety of the new crown vaccine for cancer patients has not actually been fully studied.
    The case also reminded the prospective pharmacovigilance of the safety of the new crown vaccine in cancer patients.

    Finally, the author of the paper stated that the conditions in the paper are just one case, not universal, and cancer patients are usually more susceptible to the new crown virus, and the benefits of cancer patients vaccinating the new crown vaccine far outweigh the risks.

    Therefore, it is still recommended that cancer patients receive the new crown vaccine in time.

    The link to the paper: https:// is open to reprint this article is open to reprint: just leave a message in this article to inform 
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.